跳到正文
原文
STAT 主站· Adam Feuerstein·· 2026-10-13精选AI 评分79

STAT:Neurocrine罕见病药物Vykat XR安全性担忧上升

STAT+: Concerns grow on safety issues tied to Neurocrine Biosciences rare disease drug

AI 导读

Neurocrine Biosciences的Vykat XR获批用于Prader-Willi综合征治疗18个月以来,已有七例死亡与近100例住院报告。STAT通过信息公开法案获得提交的病例报告,显示尚无法确立因果关系,但部分专家与患者倡导者认为风险已不可接受。

推荐理由

文章转述患者倡导者与专家对Vykat XR安全性的担忧及监管材料现状,适合了解该药当前争议背景。

正文 · 原文

Two months after the release of an open letter on potential safety issues tied to a rare disease drug sold by Neurocrine Biosciences, patient advocates and some experts are expressing growing alarm over the perceived risks of the therapy.

The drug, approved to treat Prader-Willi syndrome, which can cause an insatiable feeling of hunger, has been linked to the deaths of seven people and the  hospitalization of nearly 100 others — all since the treatment, called Vykat XR, was approved 18 months ago. 

Case reports on those deaths and hospitalizations that were submitted to regulators, and that were obtained by STAT through the Freedom of Information Act, do not prove causality; many of the Vykat cases involved complex medical issues and multiple medications. But some experts say the evidence is sufficient to conclude Vykat is causing unacceptable harm.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT 主站 · statnews.com